VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Stock Comparison
Amgen Inc. vs DexCom, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Amgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
DexCom, Inc.
DXCM · Nasdaq Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into DexCom, Inc.'s moat claims, evidence, and risks.
View DXCM analysisComparison highlights
- Moat score gap: DexCom, Inc. leads (82 / 100 vs 70 / 100 for Amgen Inc.).
- Segment focus: Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines); DexCom, Inc. has 1 segment (100% in Continuous glucose monitoring systems).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Amgen Inc. has 5 moat types across 3 domains; DexCom, Inc. has 5 across 3.
Primary market context
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
DexCom, Inc.
Continuous glucose monitoring systems
Global continuous glucose monitoring systems and glucose biosensing devices
Global, with FY2025 revenue 71.5% United States and 28.5% international
People with diabetes, metabolic-health users, caregivers, clinicians, payors, distributors and pharmacy channels
CGM device manufacturer, disposable sensor supplier, software/data platform and distribution partner
100%
Side-by-side metrics
Moat coverage
Shared moat types
Amgen Inc. strengths
DexCom, Inc. strengths
Segment mix
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
DexCom, Inc. segments
Full profile >Continuous glucose monitoring systems
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.